Interestingly, two small molecules with the highest binding affinities with YAP1 were identified using the virtual screening and molecular docking analysis, which underpins and warrants more research to unveil the potential of YAP1 as one potential therapeutic target for DKD. Here, YAP1 is linked to diabetic kidney disease.